Efungumab
| Monoclonal antibody | |
|---|---|
| Type | Single-chain variable fragment |
| Source | Human |
| Target | fungal Hsp90 |
| Clinical data | |
| Trade names | Mycograb |
| Intravenous | |
| Pharmacokinetic data | |
| Bioavailability | Not applicable (IV only) |
| Protein binding | High |
| Half-life | 1–2 hours |
| Identifiers | |
 | |
| None | |
| UNII |
BM86P708HW |
| Chemical data | |
| Approximately 27.2 kDa | |
 (what is this?) (verify) | |
Efungumab (trade name Mycograb) is a drug developed by NeuTec Pharma (a subsidiary of Novartis), intended to treat invasive Candida infection in combination with amphotericin B. The European Medicines Agency has twice refused to grant marketing authorization for Mycograb, citing product safety and quality issues.[1]
Chemically, efungumab is a single-chain variable fragment of a human monoclonal antibody.[2] As such, it potentially act similarly to an IgA - inhibiting by binding and blocking.
Its ability to potentiate the effects of the antifungal amphotericin B in culture were later found to be non-specific. [3]
References
- ↑ European Medicines Agency (2007). REFUSAL CHMP ASSESSMENT REPORT FOR MYCOGRAB. Procedure No. EMEA/H/C/658 PDF (370 KiB). London: European Medicines Agency. Retrieved on 2007-11-20. Detailed assessment report with comprehensive overview of reasons for refusal of marketing authorization.
- ↑ World Health Organization (2006). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 95" (PDF). WHO Drug Information 20 (2): 48.
- ↑ Nonspecific Effect of Mycograb on Amphotericin B MIC. Antimicrob Agents Chemother v.56(7); Jul 2012 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3393390/
| ||||||||||||||||||||||||||||||||||||||||||||||||||